A man with the deadliest form of brain cancer has no signs of the disease after taking an experimental drug.

Ben Trotman was 40 when he was diagnosed in 2022 with glioblastoma, the most aggressive cancerous brain tumor. Patients typically live an average of 15 months after diagnosis, and the five-year survival rate is just 6.9%.

Trotman was referred to The National Hospital for Neurology and Neurosurgery at University College London Hospitals (UCLH), where he was treated by consultant UCLH medical oncologist Dr. Paul Mulholland, as detailed in a press release.

ANCIENT 'PHARAOH'S CURSE' FUNGUS SHOWS PROMISE IN KILLING CANCER CELLS

As the only person enrolled in a trial that ultimately closed due to lack of patients, Trotman received a medication called ipilimumab, a targeted immunotherapy treatment.

Ipilimumab is an antibody that binds to a protein on immune cells (T cells). It keeps cancer cells from suppressing the immune system so it can then attack and kill the cancer, according to the National Cancer Institute.

Trotman also received radiation and chemotherapy. 

More than two years later, his quarterly scans show no signs of cancer.

"It is very unusual to have a clear scan with glioblastoma, especially when he didn’t have the follow-up surgery that had been planned to remove all of the tumor that was initially visible on scans," his oncologist, Mulholland, said in the release. 

"We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumor at bay — and it has so far, which we are delighted to see."

Two months after receiving the ipilimumab, Trotman married his wife, Emily. In April 2025, they welcomed their daughter, Mabel.

"Getting this diagnosis was the most traumatic experience — we were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live," Emily Trotman said in the release. 

"Had we not met Dr. Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation."

Ben Trotman added, "We obviously don’t know what the future holds, but having had the immunotherapy treatment and getting these encouraging scan results has given [us] a bit of hope."

"We are focused on rebuilding the life we thought we had lost and enjoying being parents."

Mulholland and his team have now opened another clinical trial for patients who have been newly diagnosed with glioblastoma.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Sixteen patients will be recruited for the trial, which is sponsored by UCL. 

The treatment will be administered at the NIHR UCLH’s Clinical Research Facility and the National Hospital for Neurology and Neurosurgery, according to the press release.

The patients will receive ipilimumab before proceeding to standard treatments that may include surgery, radiotherapy and chemotherapy.

"The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy," Mulholland said in the release.

The Win-Glio trial — nicknamed "Margaret’s Trial" — is funded by the efforts of Dame Siobhain McDonagh, sister of Margaret McDonagh, a London woman who died of glioblastoma in 2023 and was treated by Mulholland.

For more Health articles, visit www.foxnews.com/health

Ben Trotman said he is "delighted" that the new trial is moving forward with the same immunotherapy drug he received. 

"It will give people newly diagnosed with glioblastoma some hope."

Beyond the cancer risks of old oil, fried foods themselves can lead to a range of health issues, all of which negatively impact health over time

View the full post GFNC: Cooking in old oil is associated with many cancers on NOW Grenada.

AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.

The post AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma appeared first on MedCity News.

AbbVie said Monday that it would pay up to $2.1 billion to acquire Capstan Therapeutics, a startup developing CAR-T therapies for autoimmune conditions, fibrosis, and cancer. 

AbbVie will pay up to $2.1 billion in cash when the deal closes, according to a press release. The companies did not give further details about the financial terms or a timeline for completing the acquisition. 

Capstan launched in 2022 and has raised around $340 million from OrbiMed, Vida Ventures, RA Capital, Polaris Partners, and the venture teams at Pfizer, Bayer, Eli Lilly and Company, and Bristol Myers Squibb. It was last valued at around $500 million, according to Pitchbook. 

Continue to STAT+ to read the full story…

Former President Joe Biden was diagnosed with an "aggressive form" of prostate cancer that has a five-year survival rate of between 30% and 40%.

The former president's prostate cancer is characterized by a Gleason score of 9 and Grade Group 5 with bone metastasis, indicating that it is "pretty far advanced," Fox News senior medical analyst Dr. Marc Siegel said on ‘Fox Report.’

"It’s the most aggressive type," Siegel said. "That means it has the highest risk of spread — which obviously he has had."

Biden is also presenting with urinary symptoms, which is another sign that the cancer is advanced. Prostate cancer often presents as asymptomatic in its early stages, he said. 

JOE BIDEN DIAGNOSED WITH 'AGGRESSIVE FORM' OF PROSTATE CANCER WITH METASTASIS TO THE BONE

"This was found by physical examination by a prostate exam," Siegel said. "A lot of times we find an elevation in prostate-specific antigen, PSA, and then we go after it… I mean, he must have had the best possible care here. I'm a little taken aback that it's this far advanced."

Siegel said he conducts a prostate-specific antigen, or PSA, test on every male over the age of 45 years old. The test measures how much PSA is in the blood and is primarily used to screen for prostate cancer, according to Mayo Clinic. 

NEW PROSTATE CANCER TEST PINPOINTS DISEASE BETTER THAN PSA OPTION, STUDY FINDS

While the PSA test is not always a perfect indicator of prostate cancer, someone who has a rise in PSA automatically gets an MRI, Siegel said. After the MRI, a decision is made about whether to conduct a biopsy.

More than 80% of men over the age of 80 years old have some prostate cancer cells in their body, according to Siegel.

"It would be really surprising if they weren't doing a very close screening on this because everybody knows in the medical community that this is the one cancer in men you really look out for," he said. "… He doesn't seem to have a lot of risk factors that I would think about other than age, but age is enough and he's 82, so that's a big risk factor."

Doctors will likely treat Biden with hormone therapy, Siegel said. They may also attempt to radiate the lesion found on the bone or remove the prostate altogether.

PROSTATE CANCER DRUG NOW AVAILABLE TO MORE PATIENTS WITH AGGRESSIVE FORM OF DISEASE

"Sometimes they decide to do more than one therapy," Siegel said. "They might try to take the prostate out, do radiation and the hormone therapy altogether. That's not uncommon."

There are two types of medications used to treat this type of advanced prostate cancer — Lupron, which stops testosterone production, and Casodex, which stops testosterone from binding. Side effects of the medication can leave people feeling "fatigued and listless," according to Siegel.

"The other thing I'm concerned about is bone pain, because those metastases to the bone can be pretty painful," he said.

If the cancer is caught early while its still localized to the prostate gland, it’s curable "most of the time," Siegel said.

"The goal is to get it before it leaves the prostate," Siegel said. "When it's left the prostate, it becomes much more difficult to cure."

On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its experimental drug outperformed Merck’s Keytruda, the world’s best-selling drug, in non-small cell lung cancer, the disease that represents Keytruda’s biggest market.

By itself, Summit’s victory would be a dramatic story, although not an unheard of one in the unpredictable world of biotechnology. But it’s just the start. Because at the center of it is one of the industry’s most iconoclastic figures: Robert “Bob” Duggan, who became a billionaire after he bought up shares of another biotech company, Pharmacyclics, that was on the brink of failure, developed a breakthrough cancer drug, and sold the company to AbbVie for $21 billion.

Duggan, 80, is a living rebuke to a pharmaceutical industry self-image that is increasingly crafted in Cambridge, Mass. and San Francisco. Before Pharmacyclics, he had no drug industry experience, having worked in cookie stores and then surgical robots. He lacks a college degree, and is a practicing scientologist who told STAT in an interview that he reads the works of Scientology founder L. Ron Hubbard every day and who has in the past said he’d given the church more than $360 million. He speaks in long, dramatic arcs, often spelling out words, referencing their roots, or giving itemized lists.

Continue to STAT+ to read the full story…

Christina Kashiwada was traveling for work during the summer of 2018 when she noticed a small, itchy lump in her left breast.

She thought little of it at first. She did routine self-checks and kept up with medical appointments. But a relative urged her to get a mammogram. She took the advice and learned she had stage 3 breast cancer, a revelation that stunned her.

“I’m 36 years old, right?” said Kashiwada, a civil engineer in Sacramento, California. “No one’s thinking about cancer.”

About 11,000 Asian American and Pacific Islander women were diagnosed with breast cancer in 2021 and about 1,500 died. The latest federal data shows the rate of new breast cancer diagnoses in Asian American and Pacific Islander women — a group that once had relatively low rates of diagnosis — is rising much faster than that of many other racial and ethnic groups. The trend is especially sharp among young women such as Kashiwada.

About 55 of every 100,000 Asian American and Pacific Islander women under 50 were diagnosed with breast cancer in 2021, surpassing the rate for Black and Hispanic women and on par with the rate for white women, according to age-adjusted data from the National Institutes of Health. (Hispanic people can be of any race or combination of races but are grouped separately in this data.)

The rate of new breast cancer cases among Asian American and Pacific Islander women under 50 grew by about 52% from 2000 through 2021. Rates for AAPI women 50 to 64 grew 33% and rates for AAPI women 65 and older grew by 43% during that period. By comparison, the rate for women of all ages, races, and ethnicities grew by 3%.

Researchers have picked up on this trend and are racing to find out why it is occuring within this ethnically diverse group. They suspect the answer is complex, ranging from cultural shifts to pressure-filled lifestyles — yet they concede it remains a mystery and difficult for patients and their families to discuss because of cultural differences.

Helen Chew, director of the Clinical Breast Cancer Program at UC Davis Health, said the Asian American diaspora is so broad and diverse that simple explanations for the increase in breast cancer aren’t obvious.

“It’s a real trend,” Chew said, adding that “it is just difficult to tease out exactly why it is. Is it because we’re seeing an influx of people who have less access to care? Is it because of many things culturally where they may not want to come in if they see something on their breast?”

There’s urgency to solve this mystery because it’s costing lives. While women in most ethnic and racial groups are experiencing sharp declines in breast cancer death rates, about 12 of every 100,000 Asian American and Pacific Islander women of any age died from breast cancer in 2023, essentially the same death rate as in 2000, according to age-adjusted, provisional data from the Centers for Disease Control and Prevention. The breast cancer death rate among all women during that period dropped 30%.

The CDC does not break out breast cancer death rates for many different groups of Asian American women, such as those of Chinese or Korean descent. It has, though, begun distinguishing between Asian American women and Pacific Islander women.

Nearly 9,000 Asian American women died from breast cancer from 2018 through 2023, compared with about 500 Native Hawaiian and Pacific Islander women. However, breast cancer death rates were 116% higher among Native Hawaiian and Pacific Islander women than among Asian American women during that period.

Rates of pancreatic, thyroid, colon, and endometrial cancer, along with non-Hodgkin lymphoma rates, have also recently risen significantly among Asian American and Pacific Islander women under 50, NIH data show. Yet breast cancer is much more common among young AAPI women than any of those other types of cancer — especially concerning because young women are more likely to face more aggressive forms of the disease, with high mortality rates.

“We’re seeing somewhere almost around a 4% per-year increase,” said Scarlett Gomez, a professor and epidemiologist at the University of California-San Francisco’s Helen Diller Family Comprehensive Cancer Center. “We’re seeing even more than the 4% per-year increase in Asian/Pacific Islander women less than age 50.”

Gomez is a lead investigator on a large study exploring the causes of cancer in Asian Americans. She said there is not yet enough research to know what is causing the recent spike in breast cancer. The answer may involve multiple risk factors over a long period of time.

“One of the hypotheses that we're exploring there is the role of stress,” she said. “We're asking all sorts of questions about different sources of stress, different coping styles throughout the lifetime.”

It’s likely not just that there’s more screening. “We looked at trends by stage at diagnosis and we are seeing similar rates of increase across all stages of disease,” Gomez said.

Veronica Setiawan, a professor and epidemiologist at the Keck School of Medicine of the University of Southern California, said the trend may be related to Asian immigrants adopting some lifestyles that put them at higher risk. Setiawan is a breast cancer survivor who was diagnosed a few years ago at the age of 49.

“Asian women, American women, they become more westernized so they have their puberty younger now — having earlier age at [the first menstrual cycle] is associated with increased risk,” said Setiawan, who is working with Gomez on the cancer study. “Maybe giving birth later, we delay childbearing, we don't breastfeed — those are all associated with breast cancer risks.”

Moon Chen, a professor at the University of California-Davis and an expert on cancer health disparities, added that only a tiny fraction of NIH funding is devoted to researching cancer among Asian Americans.

Whatever its cause, the trend has created years of anguish for many patients.

Kashiwada underwent a mastectomy following her breast cancer diagnosis. During surgery, doctors at UC Davis Health discovered the cancer had spread to lymph nodes in her underarm. She underwent eight rounds of chemotherapy and 20 sessions of radiation treatment.

Throughout her treatments, Kashiwada kept her ordeal a secret from her grandmother, who had helped raise her. Her grandmother never knew about the diagnosis. “I didn't want her to worry about me or add stress to her,” Kashiwada said. “She just would probably never sleep if she knew that was happening. It was very important to me to protect her.”

Kashiwada moved in with her parents. Her mom took a leave from work to help take care of her.

Kashiwada’s two young children, who were 3 and 6 at the time, stayed with their dad so she could focus on her recovery.

“The kids would come over after school,” she said. “My dad would pick them up and bring them over to see me almost every day while their dad was at work.”

Kashiwada spent months regaining strength after the radiation treatments. She returned to work but with a doctor’s instruction to avoid lifting heavy objects.

Kashiwada had her final reconstructive surgery a few weeks before covid lockdowns began in 2020. But her treatment was not finished.

Her doctors had told her that estrogen fed her cancer, so they gave her medicine to put her through early menopause. The treatment was not as effective as they had hoped. Her doctor performed surgery in 2021 to remove her ovaries.

More recently, she was diagnosed with osteopenia and will start injections to stop bone loss.

Kashiwada said she has moved past many of the negative emotions she felt about her illness and wants other young women, including Asian American women like her, to be aware of their elevated risk.

“No matter how healthy you think you are, or you're exercising, or whatever you're doing, eating well, which is all the things I was doing — I would say it does not make you invincible or immune,” she said. “Not to say that you should be afraid of everything, but just be very in tune with your body and what your body's telling you.”

Phillip Reese is a data reporting specialist and an associate professor of journalism at California State University-Sacramento.

This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation. Supplemental support comes from the Asian American Journalists Association-Los Angeles through The California Endowment.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Hope your weekend was a blissful one. Today, we talk about AbbVie’s outsize marketing spend, see how GLP-1s are impacting cancer rates, and more.

Read the rest…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Read on today for some exclusive hiring news and a retraction of a high-profile paper on cancer detection.

Read the rest…

Skin cancer is the most common type of cancer in the U.S. — with one in five Americans developing the disease by the age of 70.

Melanoma is the deadliest form of skin cancer, expected to take the lives of more than 8,200 people in the U.S. this year.

This May, for Skin Cancer Awareness Month, two melanoma patients are sharing their stories of how they overcame this invasive form of the disease.

SKIN CANCER CHECKS AND SUNSCREEN: WHY THESE (STILL) MATTER VERY MUCH FOR GOOD HEALTH

One even wrongly assumed that what she was experiencing "was just a normal part of aging and sun exposure." Here's what others can learn.

Melanoma is a type of skin cancer that starts in the melanocytes, which are the cells that produce the skin’s pigmentation (color).

Most cases — but not all — are caused by exposure to ultraviolet light. Melanoma can affect people of all skin tones and types.

"Melanoma is one of the most common type of cancer in younger patients," Nayoung Lee, M.D., assistant professor of dermatology at NYU Langone Health, told Fox News Digital.

The prognosis is "very good" when melanoma is detected early, but the survival rate falls steeply when it is detected at a more advanced stage, she noted. 

"Melanoma can spread through the bloodstream to your lymph nodes and distant organs, so it is crucial to do regular skin exams to try to catch it at an early stage," Lee said.

Abby Weiner, 43, a wife and mother of three young boys living in Washington, D.C., had always been careful about protecting her skin from the sun — which is why her Oct. 2023 melanoma diagnosis was such a shock, she said.

"I had a spot on my cheek that started as a freckle and began getting darker and larger," she told Fox News Digital. 

"I assumed it was just a normal part of aging and sun exposure."

VACCINE FOR DEADLY SKIN CANCER SHOWS ‘GROUNDBREAKING’ RESULTS IN CLINICAL TRIAL

Weiner’s sister encouraged her to get it checked out — which led to a biopsy and diagnosis. 

"I was obviously shocked and frightened at first," said Weiner.  

Her melanoma was removed using Mohs surgery, a procedure in which thin layers of skin are removed one at a time. 

"I required two procedures to remove the cancer and surrounding margins," she said. "Now, most people don't even know I had surgery."

To others, Weiner’s advice is to remember to seek shade, wear sun-protective clothing, and apply a broad-spectrum, water-resistant sunscreen with an SPF of 30 or higher on a daily basis all year long. 

"I thought I was careful about protecting myself from sun exposure by wearing a hat or applying sunscreen when my family was at the pool or planning to be outdoors — but if we were eating outdoors and there wasn't a table in the shade, I would end up sitting in the sun."

Now, Weiner said she will wait a little longer for a shaded table, and she always keeps a hat and sunscreen with her.

"My sons used to have difficulty applying sunscreen and wearing hats, but now that they've seen the impact skin cancer had on me, they are more cooperative," she said.

CANCER SCREENINGS: HERE ARE 5 TYPES AND CRITICAL INFORMATION TO KNOW ABOUT EACH

Weiner also recommends that everyone gets yearly skin checks with a board-certified dermatologist. 

"I have so many friends — and even my sister, who probably saved my life — who didn't regularly see a dermatologist for a yearly skin check before they learned about my melanoma."

Steve Murray, 68, of the greater Washington, D.C. area, has worked in construction for several decades. 

During his childhood, Murray spent summers at the beach in Ocean City, New Jersey, and winter visits to Florida, where he was exposed to the sun and didn’t do much to protect himself.

In the late 1990s, Murray was diagnosed with basal cell carcinoma, the most common type of skin cancer, and squamous cell carcinoma, a variation of skin cancer that tends to develop in people who have had a lot of sun exposure.

In 2008, he was diagnosed with melanoma.

"My initial symptoms included itching and scaling on my head, followed by irritation," he told Fox News Digital. 

"Then there was discoloration and irregularity in the shape of my moles."

Initially, Murray feared the worst — "mainly death" — but his dermatologist determined that the melanoma was only on his scalp and hadn’t traveled to his lymph nodes.

Like Weiner, Murray had Mohs surgery to get rid of the cancer — and he was cleared.

VIRGINIA HIGH SCHOOL STUDENT CREATES SOAP TO FIGHT SKIN CANCER, IS AWARDED $25K: 'REMARKABLE EFFORT'

Since that diagnosis, Murray has had several more bouts of skin cancer.

In 2024, he underwent two surgeries for squamous cell carcinoma on his hand and back. 

Now, Murray visits the dermatologist every three to six months. Also, he always wears a hat, sunscreen and long sleeves whenever possible to protect himself from the sun.

Murray’s advice to others is to make sun protection a priority when outdoors.

"You don’t notice at the time of initial exposure, but it haunts you later in life when you start developing pre-cancers and skin cancers like squamous cell carcinoma and melanoma that require immediate attention," he told Fox News Digital.

"Capturing these pre-cancers and cancers of the skin must be diagnosed early with regular checkups," he added. "Failure to do so could lead to death."

Dr. Lee of NYU Langone Health shared five tips to help prevent potentially deadly skin cancers like melanoma.

"Avoiding a burn is really only half the battle — there is no such thing as a base tan," Lee said. "Damaged skin is damaged skin."

For a safer way to achieve a sun-kissed glow on your first beach day of the summer, Lee recommends using self-tanning products.

When applying sunscreen, Lee recommends using 1 ounce, which would fill a shot glass. 

IF YOU OR YOUR CHILDREN HAVE FRECKLES, HERE'S WHAT YOUR SKIN IS TRYING TO TELL YOU

"It should have a sun protection factor (SPF) of 30 and say ‘broad-spectrum’ on the label, which protects against the sun’s UVA and UVB rays," she said. 

Reapply at least every 80 minutes, or more often if you’re sweating or swimming.

Physical sunscreen contains zinc or titanium, which is superior in efficacy to chemical sunscreen, according to Lee.

"Check your skin regularly so you know what’s normal and to notice any changes or new growths," Lee advised. 

"Seek a dermatologist’s evaluation if you notice a changing, bleeding or persistently itchy spot."

This is the best way to determine if any mole or blemish is cancerous, according to Lee. 

The ABCDE rule tells you what to look for when examining your skin. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The A stands for asymmetrical. "Noncancerous moles are typically symmetrical," Lee said. 

B is for border, as the border of a cancerous spot or mole may be irregular or blurred. 

C stands for color. "A typical mole tends to be evenly colored, usually a single shade of brown," Lee noted. 

"Not all melanomas are dark and scary-appearing. They can be amelanotic, which means they can be more skin colored or pink."

D stands for diameter of the spot or mole, which may be a warning sign if it’s larger than 6 millimeters, according to Lee.

If the spot is evolving, which is what E stands for, it might be of concern.

Lee added, "Because melanomas can vary in appearance, it is important to see a dermatologist regularly for skin exams if you have a history of significant sun exposure, have many atypical appearing moles, or a family or personal history of melanoma so that you have an experienced set of eyes looking at any spots of concern."

For more Health articles, visit www.foxnews.com/health.